ED
Editas Medicine, Inc.
EDIT · NASDAQ
$2.71 +1.50% (+$0.04)
1M -5.90%
Market Cap $415.9M
P/E Ratio -
Div. Yield -
ROE 196.63%
Bulios Fair Price
$2.32
14.4% downside
Current Price
$2.71
Undervalued Fair Value Overvalued
According to Bulios Fair Price, EDIT is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
3/9Valuation
26 /100
Expensive P/S 8.85x
P/B 3.95x
P/E N/A
Growth
78 /100
Growing Rev. growth 27.15%
Book val. growth 57.71%
EPS growth N/A
Profitability
20 /100
Weak Gross margin 56.90%
Net margin 157.32%
FCF margin 256.46%
Quality
3 /100
Poor ROIC 46.81%
ROE 196.63%
Asset turnover 0.20x
Debt
100 /100
Low Debt/Equity 0.15x
Current ratio 3.19x
Int. coverage 34.55x
Stability
13 /100
Unstable Beta 2.09x
Rev. volatility 185.50%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about EDIT
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Gilmore O'Neill
Employees
87
Headquarters
Cambridge
Upcoming events
09 NOV
Earnings
Upcoming earnings report